Phylogica Ltd - 16/03/2006
You have no credits left. To view this article subscribe to Business News.
You have used {{points}} and have {{current_points}} remaining. Your credits will reset on {{reset_date}}.
This article is part of a special report and is available to paid Business News subscribers only.
You can purchase access to this special report or subscribe to Business News.
You can purchase access to this special report or subscribe to Business News.
This article is premium content and is available to paid Business News subscribers only.
Subscribe to Business News.
Subscribe to Business News.
Tuesday, 21 March, 2006 - 21:00
Has announced its first commercial partnering agreement with international biotechnology company Opsona Therapeutics to develop a new class of Phylomer® drugs targeting inflammatory diseases